Pfizer Thinks Small: Partnership With Protalix On Gaucher Drug Eyes Cheaper Plant-Based Production
Executive Summary
Pfizer's licensing deal with Protalix for global rights to the enzyme replacement therapy taliglucerase for the treatment of Gaucher disease, announced Dec. 1, signals the drug giant's interest in the orphan drug space. It also plays into the company's biosimilar strategy, given that taliglucerase will likely be positioned as a lower-cost alternative to Genzyme's Cerezyme (imiglucerase)
You may also be interested in...
EMA Orphan Approval Path Seems More Twisty After Pfizer/Protalix’s Elelyso Stumbles
The European Medicines Agency will not recommend Pfizer/Protalix’s Elelyso for type 1 Gaucher, maintaining that it is too similar to Shire’s Vpriv, despite the firms’ argument that their product offers better bone marrow data and alleviates shortage concerns.
Armed With A Range Of Insulins, Pfizer Is Weeks Away From Its First Biosimilars Rollout In India - BIO 2011 Conference
WASHINGTON - Pfizer Inc. is all set to kick-off its journey into the world of biosimilars as it gives finishing touches to the launch of a range of insulins in India. The company is counting on a set of value propositions, high quality and competitive pricing to emerge as a "natural leader" in the Indian market
Armed With A Range Of Insulins, Pfizer Is Weeks Away From Its First Biosimilar Rollout In India - BIO 2011 Conference
The company is counting on a set of value propositions, high quality and competitive pricing to emerge as a "natural leader" in the Indian market.